MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Saved in:
| Title: | MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. |
|---|---|
| Authors: | Stroh J; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Seckinger A; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Heider M; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Rudelius M; Institute of Pathology, Ludwigs Maximilians University, Munich, Germany., Eichner R; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Schick M; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany., Slawska J; Department of Medicine III, Klinikum rechts der Isar, and.; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany., Emde-Rajaratnam M; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Salwender H; Asklepios Tumorzentrum Hamburg, Hamburg, Germany.; AK Altona, Hamburg, Germany.; AK St. Georg, Hamburg, Germany., Bertsch U; Department of Internal Medicine V, and., Goldschmidt H; Department of Internal Medicine V, and.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany., Weisel K; Department of Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Scheid C; Department of Internal Medicine I, and.; Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany., Keller U; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and.; Max-Delbrück Center for Molecular Medicine, Berlin, Germany., Hose D; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Bassermann F; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and. |
| Source: | Blood advances [Blood Adv] 2022 Jan 25; Vol. 6 (2), pp. 515-520. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
